Tarsus Pharmaceuticals Inc. (TARS)
NASDAQ (NGS) NASDAQ (NGS) Primary 
Tarsus Pharmaceuticals, Inc. (TARS) Q4 2024 Earnings Call Transcript
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS ) Q4 2024 Earnings Conference Call February 25, 2025 8:00 AM ET Company Participants David Nakasone - Head of IR Bobby Azamian - CEO and Chairman Aziz Mottiwala - CCO Seshadri Neervannan - COO Jeff Farrow - CFO and CSO Conference Call Participants Francois Brisebois - Oppenheimer Corey Jubinville - Life Sci Capital Jason Gerberry - Bank of America Oren Livnat - HC Wainright Eddie Hickman - Guggenheim Securities Andrea Newkirk - Goldman Sachs Lachlan Hanbury-Brown - William Blair Operator Good morning, and welcome to Tarsus Year End 2024 Financial Results Conference Call. As a reminder, this call is being recorded.
Tarsus Pharmaceuticals, Inc. (TARS) Reports Q4 Loss, Tops Revenue Estimates
Tarsus Pharmaceuticals, Inc. (TARS) came out with a quarterly loss of $0.60 per share versus the Zacks Consensus Estimate of a loss of $0.68. This compares to loss of $1.31 per share a year ago.
Down -9.11% in 4 Weeks, Here's Why Tarsus Pharmaceuticals (TARS) Looks Ripe for a Turnaround
The heavy selling pressure might have exhausted for Tarsus Pharmaceuticals (TARS) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Wall Street Analysts Think Tarsus Pharmaceuticals (TARS) Could Surge 26.98%: Read This Before Placing a Bet
The consensus price target hints at a 27% upside potential for Tarsus Pharmaceuticals (TARS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Wall Street Analysts Believe Tarsus Pharmaceuticals (TARS) Could Rally 41.09%: Here's is How to Trade
The average of price targets set by Wall Street analysts indicates a potential upside of 41.1% in Tarsus Pharmaceuticals (TARS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Tarsus Pharmaceuticals, Inc. (TARS) Q3 2024 Earnings Call Transcript
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS ) Q3 2024 Earnings Conference Call November 13, 2024 4:30 PM ET Company Participants David Nakasone - Head, IR Bobby Azamian - Chairman & CEO Aziz Mottiwala - Chief Commercial Officer Jeff Farrow - CFO and CSO Sesha Neervannan - COO Elizabeth Yeu - Chief Medical Officer Conference Call Participants Eddie Hickman - Guggenheim Securities Lachlan Hanbury-Brown - William Blair Andrea Newkirk - Goldman Sachs Oren Livnat - HC Wainwright Balaji Prasad - Barclays Jason Gerberry - Bank of America Merrill Lynch Corey Jubinville - Life Sci Capital Francois Brisebois - Oppenheimer Operator Welcome to Tarsus' Third Quarter 2024 Financial Results Conference Call. As a reminder, this call is being recorded at this time, I would like to turn the call over to David Nakasone, Head of Investor Relations, to lead off the call.
Tarsus Pharmaceuticals, Inc. (TARS) Reports Q3 Loss, Tops Revenue Estimates
Tarsus Pharmaceuticals, Inc. (TARS) came out with a quarterly loss of $0.61 per share versus the Zacks Consensus Estimate of a loss of $0.90. This compares to loss of $1.28 per share a year ago.
Tarsus Pharmaceuticals, Inc. (TARS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Tarsus Pharmaceuticals (TARS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Tarsus Pharmaceuticals (TARS) Surges 10.6%: Is This an Indication of Further Gains?
Tarsus Pharmaceuticals (TARS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Tarsus Pharmaceuticals: Unlocking Growth Potential With Eye Care Innovations
Tarsus Pharmaceuticals, Inc.'s Xdemvy, the first FDA-approved treatment for demodex blepharitis, has shown significant efficacy and rapid revenue growth, with $40.8M revenue in Q2 2024. The company is expanding its pipeline to target meibomian gland disease and rosacea, with promising Phase 2 results and ongoing FDA discussions. Strong financials with $323M in cash reserves, a healthy current ratio, and a projected positive cash flow by Q3 2024 support robust growth.
Tarsus Pharmaceuticals: Strong Execution In Eye Disease Treatment
Tarsus Pharma has a drug for Demodex blepharitis and multiple late-stage assets in its pipeline, including lotilaner for various formulations. The company has seen a 65% increase in stock value, with a $1 billion market opportunity in the initial addressable segment alone. TARS has promising data in trials for various conditions, including Lyme disease and Meibomian gland disease, with potential preventive and therapeutic benefits.
Tarsus Pharmaceuticals, Inc. (TARS) Q2 2024 Earnings Call Transcript
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS ) Q2 2024 Earnings Conference Call August 8, 2024 4:30 PM ET Company Participants David Nakasone - Head, Investor Relations Bobby Azamian - Chairman and CEO Aziz Mottiwala - Chief Commercial Officer Jeff Farrow - Chief Financial Officer and CSO Sesha Neervannan - Chief Operating Officer Conference Call Participants Tim Lugo - William Blair Pavan Patel - BofA Dennis Kennedy - LifeSci Capital Talani Usman - Goldman Sachs Frank Brisebois - Oppenheimer Michaela Diverio - Barclays Eddie Hickman - Guggenheim Securities Operator Good afternoon. And welcome to the Tarsus' Second Quarter 2024 Financial Results Conference Call.
